Therefore, there was an inevitable bias in the enrollment of the cases; it differed from the general breast cancer cohort in terms of larger invasive tumor sizes, more ER-negative cases, and higher Ki67 cases (Supplementary Table S2). This evidence concerns the gene ESR1 and breast cancer.